Trial Profile

An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saposin C (Primary)
Indications Tumours
Focus Therapeutic Use
Acronyms ETERNITI
Sponsors Bexion Pharmaceuticals

Most Recent Events

20 Dec 2024 Status changed from recruiting to discontinued as Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial
28 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
28 Aug 2024 Planned primary completion date changed from 1 May 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com